Xenetic Biosciences IncNASDAQ:XBIO
- LAST PRICE3.6900
- TODAY'S CHANGE (%)0.0300 (0.8197%)
- Bid / Lots3.5700/ 5
- Ask / Lots4.0000/ 3
- Open / Previous Close3.6700 / 3.6600
- Day Range
- 52 Week Range
- Volume2,698
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | XBIO |
|---|---|---|
| 09:32 ET | 217 | 3.67 |
| 11:54 ET | 143 | 3.66 |
| 03:46 ET | 156 | 3.67 |
| 03:55 ET | 100 | 3.73 |
| 04:00 ET | 1174 | 3.69 |
Nov 13, 2024
Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results, from 8:31AM ET on Wednesday Nov 13, 2024 by Dow Jones
8:31AM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 12, 2024
Nov 7, 2024
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform, from 9:02AM ET on Thursday Nov 07, 2024 by Dow Jones
9:02AM ET on Thursday Nov 07, 2024 by Dow Jones
Oct 22, 2024
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024, from 8:48AM ET on Tuesday Oct 22, 2024 by Dow Jones
8:48AM ET on Tuesday Oct 22, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Xenetic Biosciences Inc | 5.7M | -1.2x | --- |
Intelligent Bio Solutions Inc | 6.5M | -0.1x | --- |
Senti Biosciences Inc | 9.8M | -0.1x | --- |
Talis Biomedical Corp | 3.4M | -0.1x | --- |
Helix BioMedix Inc | 3.4M | -1.0x | --- |
Infinity Pharmaceuticals Inc | 90.0 | 0.0x | --- |
Company Information
Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. It is focused on advancing the development of its DNase platform toward a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors. Its systemic DNase program is initially targeting multi-billion-dollar indications including pancreatic cancer, which includes pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma (CRC) and other gastrointestinal cancers. These are all cancer indications with significant unmet need, and with opportunities for substantial improvement of the available therapeutic options.
Contact Information
- Headquarters
- 945 Concord St.FRAMINGHAM, MA, United States 01701
- Phone
- 781-778-7720
- Fax
- ---
Executives
- Independent Chairman of the Board
- Adam Logal
- Interim Chief Executive Officer, Chief Financial Officer
- James Parslow
- Independent Director
- Grigory Borisenko
- Independent Director
- James Callaway
- Independent Director
- Firdaus Dastoor
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.7M |
|---|---|
Revenue (TTM) | $2.5M |
Shares Outstanding | 1.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.25 |
EPS | $-3.05 |
Book Value | $6.36 |
P/E Ratio | -1.2x |
Price/Sales (TTM) | 2.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -198.71% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
